Cargando…

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy

OBJECTIVES: The Dolutegravir Monotherapy for HIV (DOMONO; NCT02401828) study showed that maintenance monotherapy with dolutegravir (DTG) is associated with virological failure (VF) and leads to DTG resistance and as a result should not be used. However, data on clinical and virological factors assoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wijting, IEA, Rutsaert, SL, Rokx, C, Burger, DM, Verbon, A, van Kampen, JJA, Boucher, CAB, Rijnders, BJA, Vandekerckhove, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586017/ https://www.ncbi.nlm.nih.gov/pubmed/30270543 http://dx.doi.org/10.1111/hiv.12675

Ejemplares similares

The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study
por: Rokx, Casper, et al.
Publicado: (2014)

Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials
por: Fournier, Anna L, et al.
Publicado: (2022)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV
por: Sangaré, Mohamed N’dongo, et al.
Publicado: (2020)

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis
por: Wandeler, Gilles, et al.
Publicado: (2019)

549. Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
por: Gibson, Amanda, et al.
Publicado: (2018)

Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving
por: Popping, Stephanie, et al.
Publicado: (2019)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa
por: Pillay, D, et al.
Publicado: (2010)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium
por: Rokx, C., et al.
Publicado: (2021)

Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens
por: Batterham, Rachel L, et al.
Publicado: (2023)

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
por: Wang, Ruolan, et al.
Publicado: (2023)

1603. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2023)

Switch to dolutegravir is well tolerated in Thais with HIV infection
por: Goh, Orlanda Q, et al.
Publicado: (2019)

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible
por: Pena, M J, et al.
Publicado: (2018)

Switching From a Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy–suppressed Human Immunodeficiency Virus–infected Individuals
por: Morón-López, Sara, et al.
Publicado: (2019)

HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report
por: van Kampen, Jeroen J.A., et al.
Publicado: (2022)

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
por: Jörimann, Lisa, et al.
Publicado: (2023)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
por: Saple, Dattatray, et al.
Publicado: (2022)

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark
por: Pedersen, Karen Brorup Heje, et al.
Publicado: (2023)

Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study
por: Esber, Allahna, et al.
Publicado: (2022)

Virological efficacy of PI monotherapy for HIV-1 in clinical practice
por: El Bouzidi, Kate, et al.
Publicado: (2016)

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2021)

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
por: Spinner, Christoph D, et al.
Publicado: (2020)

Urgent orotracheal intubation induces transient bacteremia in critically ill patients
por: Rijnders, BJA, et al.
Publicado: (2000)

2486. Clinical Outcomes of Patients Treated with Dolutegravir Functional Monotherapy or Dolutegravir plus an Active Non-cytosine Nucleoside Analog: A Retrospective Observational Cohort Study of Treatment-Experienced Patients
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
por: Gatell, José M., et al.
Publicado: (2017)

Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment
por: Dijkstra, Maartje, et al.
Publicado: (2021)

DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fn3rbr77ebu97kbjjnvhfn6mhm